AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee

PHASE3CompletedINTERVENTIONAL
Enrollment

168

Participants

Timeline

Start Date

June 19, 2017

Primary Completion Date

December 7, 2017

Study Completion Date

December 7, 2017

Conditions
Osteoarthritis, KneeKnee OsteoarthritisKnee ArthritisKnee Pain Chronic
Interventions
BIOLOGICAL

4 mL injection of Ampion

4 mL injection of Ampion

DRUG

4 mL Injection of Placebo

4 mL Injection of Placebo

Trial Locations (13)

21702

Arthritis Treatment Center, Frederick

29406

Coastal Carolina Center at Lowcountry Orthopaedics, North Charleston

30060

Drug Studies America, Marietta

35205

Central Research Associates, Inc., Birmingham

60406

Healthcare Research Netword, Blue Island

63042

Healthcare Network Research, Hazelwood

67207

Heartland Research Associates, Wichita

78745

Tekton Research, Austin

91360

Westlake Medical Research, Thousand Oaks

92024

CORE Orthopaedic Medical Center, Encinitas

92103

Artemis Institute for Clinical Research, San Diego

92835

St. Joseph Heritage, Fullerton

98007

Northwest Clinical Research Center, Bellevue

Sponsors
All Listed Sponsors
lead

Ampio Pharmaceuticals. Inc.

INDUSTRY

NCT03182686 - AP-003-C Study to Confirm the Efficacy of Ampion™ in Adults With Pain Due to Severe Osteoarthritis of the Knee | Biotech Hunter | Biotech Hunter